| 4-Aminopyridine | |
|---|---|
|
pyridin-4-amine |
|
|
Other names
4-pyridinamine, 4-Pyridylamine, Fampridine |
|
| Identifiers | |
| CAS number | 504-24-5 |
| PubChem | 1727 |
| ChemSpider | 1664 |
| UNII | BH3B64OKL9 |
| KEGG | D04127 |
| MeSH | 4-Aminopyridine |
| ChEBI | CHEBI:34385 |
| ChEMBL | CHEMBL284348 |
| IUPHAR ligand | 2416 |
| ATC code | N07 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C5H6N2 |
| Molar mass | 94.1146 |
| Appearance | colourless solid |
| Melting point |
155-158 °C |
| Boiling point |
273 °C, 546 K, 523 °F |
| Solubility in water | polar organic solvents |
| Pharmacology | |
| Bioavailability | 96% |
| Routes of administration |
Oral |
| Legal status |
℞-only(US) |
| Pregnancy category |
C(US) |
| (verify) (what is: /?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
4-Aminopyridine (INN fampridine, USAN dalfampridine) is an organic compound with the chemical formula C5H4N–NH2. The molecule is one of the three isomeric amines of pyridine. It is used primarily as a research tool, in characterizing subtypes of potassium channel, and has also been used to manage some of the symptoms of multiple sclerosis,[1][2] and is indicated for symptomatic improvement of walking in adults with several variations of the disease.[3] The drug has orphan drug status in the United States under the trade name Neurelan. It was undergoing Phase III clinical trials as of 2008[update],[4] and the U.S. Food and Drug Administration (FDA) approved the compound on January 22, 2010.[5] Fampridine is also marketed as Ampyra (pronounced "am-PEER-ah," according to the maker's website) in the United States by Acorda Therapeutics[5][6] and as Fampyra in Europe.
Contents |
4-Aminopyridine (4-AP) is prepared by the decarbonylation of pyridine-4-carboxamide using sodium hypochlorite via the Hofmann rearrangement. The pyridine carboxamide is generated from the corresponding nitrile, which in turn is obtained from ammoxidation of 4-methylpyridine.[7]
The largest scale industrial application of 4-aminopyridine is as a precursor to the drug pinacidil, which affects potassium ion channels.
In the laboratory, 4-AP is a useful pharmacological tool in studying various potassium conductances in physiology and biophysics. It is a relatively selective blocker of members of Kv1 (Shaker, KCNA) family of voltage-activated K+ channels. At concentration of 1 mM it selectively and reversibly inhibits Shaker channels without significant effect on other sodium, calcium, and potassium conductances.
4-Aminopyridine is also used as a bird control agent, under the trade name Avitrol; it causes convulsions and typically death, depending on dosage.[8] The use of 4-aminopyridine in bird control has been criticized by the Humane Society of the United States.[9]
Fampridine has been used clinically in Lambert-Eaton myasthenic syndrome and multiple sclerosis. It acts by blocking potassium channels, prolonging action potentials and thereby increasing neurotransmitter release at the neuromuscular junction.[10] The drug has been shown to reverse tetrodotoxin toxicity in animal experiments.[11]
Fampridine has been shown to improve visual function and motor skills and relieve fatigue in patients with multiple sclerosis (MS). 4-AP is most effective in patients with the chronic progressive form of MS, in patients who are temperature sensitive, and in patients who have had MS for longer than three years. Common side effects include dizziness, nervousness and nausea, and the incidence of adverse effects was shown to be less than 5% in all studies.
4-AP works as a potassium channel blocker. Electrophysiologic studies of demyelinated axons show that augmented potassium currents increase extracellular potassium ion concentration which decreases action potential duration and amplitude which may cause conduction failure. Potassium channel blockade reverses this effect. A study has shown that 4-AP is a potent calcium channel activator and can improve synaptic and neuromuscular function by directly acting on the calcium channel beta subunit.[12]
MS patients treated with 4-AP exhibited a response rate of 29.5% to 80%. A long-term study (32 months) indicated that 80-90% of patients who initially responded to 4-AP exhibited long-term benefits. Although improving symptoms, 4-AP does not inhibit progression of MS.
Spinal cord injury patients have also seen improvement with 4-AP therapy. These improvements include sensory, motor and pulmonary function, with a decrease in spasticity and pain.[13]
Case reports have shown that overdoses with 4-AP can lead to paresthesias, seizures,[14] and atrial fibrillation.[15]
The drug was originally intended, by Acorda Therapeutics, to have the brand name Amaya, however the name was changed to Ampyra to avoid potential confusion with other marketed pharmaceuticals.[16]
|
||||||||
|
|||||||||||||||||||